PR Newswire REYKJAVÍK, Iceland, Aug. 28, 2024 REYKJAVÍK, Iceland, Aug. 28, 2024 /PRNewswire/ -- A new study conducted by an international team of researchers has unveiled a pioneering approach to boosting the production of active vitamin B12 ...
PR Newswire TORONTO, ON, Aug. 26, 2024 The Super Patch Company will present its latest data showcasing the advances in the treatment for patients experiencing sleep or insomnia-related symptoms at the 27th European Sleep Research Society and ...
RIYADH, Saudi Arabia, Aug. 23, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) solidifies its medical education and research leadership through its Academic & Training Affairs (ATA) Department, which ...
PR Newswire NEW TAIPEI CITY, Taiwan, Aug. 19, 2024 GlycoNex plans to initiate Phase 3 clinical program of SPD8 in osteoporosis, targeting a multibillion USD global market opportunity NEW TAIPEI CITY, Taiwan, Aug. 19, 2024 /PRNewswire/ ...
PR Newswire LOS ANGELES, Aug. 13, 2024 LOS ANGELES, Aug. 13, 2024 /PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, today announced that the first ...
WASHINGTON , Aug. 2, 2024 /PRNewswire/ -- A groundbreaking study published today in Frontiers in Psychiatry reveals that over sixty individuals with eating disorders have undergone assisted death in Belgium , the Netherlands , and ...
LOS ANGELES , July 30, 2024 /PRNewswire/ -- Nervonik, a medical device startup focusing on neurotechnology approaches to peripheral nerve stimulation, has received approval to conduct a first-in-human feasibility study utilizing its ...
KANAZAWA, Japan , July 29, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, IMDEA Nanoscience ( Madrid, Spain ) and CNB-CSIC ( Madrid, Spain ) report in ACS Nano experiments that ...
Study Showed High Accuracy in Determining Amyloid Burden Across All Stages of Alzheimer's Disease Progression, Supporting Early Detection, Treatment, Interventions and Tracking ALZpath pTau217 Antibody Has Now Been Utilized in Over 40 ...
SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, Europe and Israel TEL AVIV, Israel , July 24, 2024 /PRNewswire/ -- SoniVie , which has developed a novel ...
Women get less restorative sleep than men because of their lifestyles and caregiving roles. They sleep less and wake up more often. A new study published in the journal Scientific Reports experimented on mice to find the sleep ...
Neonatal hypoxic-ischemic encephalopathy (HIE) is a brain dysfunction condition in newborns due to inadequate oxygen and blow flow to the brain at term or near birth. It affects 1-2 per 1,000 live births in high-resource countries . HIE is the reason for the deaths of over half a million worldwide each year. Therapeutic hypothermia is the standard treatment for moderate to severe HIE. Many infants treated with hypothermia still experience significant motor, cognitive and behavioral disabilities by school age. In low-income regions therapeutic hypothermia is unavailable and the need for new, accessible treatment is urgent. Therapies for Neuroprotection in Neonatal Hypoxic-Ischemic Encephalopathy A recent review has highlighted cutting-edge approaches to protect the newborn brain. These therapies target complex mechanisms of HIE related brain injury including inflammation, oxidative stress and cell death. Anti-excitotoxic agents like magnesium sulfate and xenon can limit brain damage caused by excessive glutamate release. Antioxidants such as allopurinol and melatonin reduce oxidative stress and improve the condition when combined with other therapies. Multi-mechanism agents like cannabidiol and caffeine promote neuroregeneration while addressing multiple pathways of injury. Stem cell therapy can repair brain damage through regenerative mechanisms. Challenges in Implementing Alternative Therapies Preclinical studies show promising results but implementing these therapies into effective clinical treatments for neonatal HIE presents many difficulties: Identifying the ideal time for administering neuroprotective therapies with the timing of hypoxic-ischemic events is important. The timing, severity and location of brain injury in hypoxic-ischemic encephalopathy can vary significantly between individuals. Need for reliable biomarkers that can assess the severity and progression of brain injury in real time, which can lead to more personalized and accurate treatment. Safe and effective delivery of these therapies to infants poses a significant challenge. Advancements in personalized medicine and combined therapies can improve treating newborns with HIE. The development of affordable and accessible treatments can revolutionize care for this life-altering condition and give hope to families. Reference: Neuroprotection for neonatal hypoxic-ischemic encephalopathy: a review of novel therapies evaluated in clinical studies- (https:...
A new study has revealed that young adults at risk of psychosis exhibit reduced brain connectivity, a deficiency that seems to be exacerbated by cannabis use. This finding opens the door for developing treatments for psychosis that address symptoms ...
Vagus nerve stimulation may help alleviate the symptoms of inflammatory bowel disease (IBD), suggests a new study. According to a team of researchers at Duke University School of Medicine, targeting the nervous system could help reduce the ...
Cardiovascular disease and dementia are major public health concerns that place a substantial strain on healthcare systems and society. A recent study from the Karolinska Institute in Sweden reveals that prolonged use of commonly prescribed ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers